Nonoperative Management Shows Promising Results for Anal Adenocarcinoma

Anal adenocarcinoma can be effectively treated with total neoadjuvant therapy and nonoperative management, according to a retrospective analysis conducted at a comprehensive cancer center. The study included 70 patients, out of which 77% received neoadjuvant therapy. Patients who underwent total neoadjuvant therapy had a higher proportion of successful watch-and-wait management compared to those who received single neoadjuvant modality therapy. Tumor regrowth rate was 22% in the total neoadjuvant therapy group. The 5-year overall survival rate for the total neoadjuvant therapy group was 61% and colostomy was avoided in 50% of these patients.